logo
Taxation Of Stock Options For Foreign Nationals Working In The U.S.

Taxation Of Stock Options For Foreign Nationals Working In The U.S.

Forbes07-05-2025
Stock options can be a lucrative form of compensation, but for foreign nationals who work in the ... More U.S., they present unique tax challenges. The U.S. retains taxing rights over income derived from U.S. employment, even after a person becomes an NRA. Understanding how the U.S. sources stock option income, potential double taxation risks, foreign tax credits and tax treaty possibilities are all critical for minimizing tax liability. getty
Many foreign persons are employed in America and are given stock options as an incentive by the companies for which they work. When a foreign national works in the U.S. and is granted stock options, the taxation of these options can become complex, especially if the individual later leaves the U.S. and becomes a nonresident alien for tax purposes. This article examines how the U.S. taxes foreign individuals on stock options received for work carried out in America and the tax issues they face after leaving the U.S. and becoming NRAs.
This article discusses non-statutory stock options , which are more commonly granted since they involve fewer restrictions and are easier to administer. When a taxpayer working in the U.S. is granted NSOs, there is typically no immediate tax liability. NSOs are not taxed at grant because these options generally lack a "readily ascertainable fair market value." As a result, taxation is deferred until the options are exercised.
It is worth noting that problems can arise if the option strike price is set below the fair market value of the shares at the time of grant or if the plan otherwise runs afoul of Internal Revenue Code Section 409A, which governs deferred compensation. In those cases, the employee might owe tax and penalties immediately, even without having exercised the options. This is why it is important that the compensation package be reviewed by a tax professional.
Options generally vest over time. A common schedule is four years with a one-year cliff. This means that no options vest until the employee has completed one year of employment. After that, 25% of the options vest, with the remainder vesting monthly or quarterly over the next three years.
The right to exercise the options is tied to this vesting schedule. Once vested, exercising the options triggers taxation on the difference between the fair market value of the shares at the time of exercise and the option strike price. The difference is treated as ordinary compensation income. For example, if an individual pays $30 per share to exercise the option and the FMV at that time is $100, they must report $70 per share as ordinary compensation income.
For the foreign national, the key issue is whether the U.S. still has the right to tax this income if the individual is no longer a tax resident when the option is exercised. The general rule is that compensation for services performed in the U.S. remains U.S.-sourced income. Since stock options are considered deferred compensation, the IRS applies specific income sourcing rules to determine how much of the income is taxable in the U.S. regardless of where the individual is living at the time of exercise.
This 'grant-to-vesting' sourcing rule determines how much of the income should be treated as having a U.S. source. This sourcing rule compares days worked in the U.S. and outside the U.S. during the period between the date the options were granted and the date the stock options became exercisable (the vesting date). If, for instance, half of the vesting period occurred while the individual was working in America Youtube, then half of the income would be treated as having a U.S.-source and would be taxable by the U.S., even though the option was exercised after the individual became a nonresident alien.
Thus, even after leaving the U.S., foreign nationals may owe tax on stock option income tied to services performed while they were in the U.S. Income treated as U.S.-sourced would be subject to withholding by the U.S. employer, typically at a flat 30% rate, unless a tax treaty applied providing a reduced rate or exemption. Double Taxation Is Possible
A foreign country may also tax the stock option income. This means when the taxpayer leaves the U.S. and resides abroad, there is a risk of double taxation. Some countries tax stock options at exercise (in the same manner as the U.S.), while others impose tax only when the stock is sold. Using foreign tax credits or treaty benefits can reduce the tax impact, but when U.S. law and foreign law are involved, it becomes complex and is best examined with an international U.S. tax professional. U.S. Tax Upon Later Sale Of The Stock
Once the taxpayer has purchased the stock by exercising the option, any future gain upon a later sale will be treated as capital gain. It is no longer taxed as ordinary income. If the stock is sold while the foreign individual is still a U.S. tax resident, the gain is taxed as either short- or long-term capital gain. If the stock was held for over 1 year it is long-term gain and taxed at preferential rates of 15% or 20%. The holding period starts on the day after the stock was acquired by exercising the option.
If an individual is an NRA when selling the stock, the gain is generally not taxed by the U.S. pursuant to a special tax rule for foreign investors without significant physical presence. This difference in tax treatment makes it crucial to know one's U.S. tax residency status at the time of sale. For those with green cards, it is critical to properly sever U.S. tax resident status. Taxation on worldwide income will continue until U.S. tax residency is severed according to specific and detailed tax rules. Many green card holders do not realize that it is possible to have lost the right to live in the U.S. under the immigration rules, but still be subject to U.S. taxation under the tax laws.
Example of Tax Savings
Elena, a foreign national living and working in America was granted 10,000 NSOs in January 2022 with a strike price of $10 per share, which matched the fair market value of the shares at the time. The options vested over four years; 25% vested in January 2023 and the rest vested monthly thereafter. In 2025, while she was still a U.S. resident, Elena exercised 7,500 of her vested options when the shares were valued at $30. This resulted in a $150,000 spread between the price at which the shares were trading at the time of exercise and the strike price (7500 x $30 = $225,000 MINUS 7500 x $10 = $75,000). This amount is treated as ordinary compensation income on which Elena will pay U.S. tax at her marginal tax rate.
Later that year, assume Elena leaves America and becomes an NRA. In 2026, assume she exercises her remaining 2,500 options at a time when the fair market value had gone up to $35 per share. Under the 'grant-to-vesting' source rule, the portion of income attributable to Elena's services performed while in the U.S. remains taxable. If half of the vesting occurred during her performance of services in the U.S., then half of the $62,500 gain is treated as U.S.-sourced compensation. As an NRA, Elena will be subject to 30% withholding on that portion, unless a tax treaty applies to reduce it.
By exercising her remaining options after she became an NRA, Elena avoided U.S. taxation on the portion of the income tied to her non-U.S. service. This results in significant tax savings that would not have been available had she exercised everything while still living in the U.S. Stock Options And State Taxation
State taxation is a crucial consideration when employees receive stock options, particularly if they have lived or worked in multiple states before exercising the options. Many U.S. states allocate stock option income based on where the employee performed services during the vesting period. Even if an individual moves to another state, or becomes an NRA, they may still owe state taxes on the portion of the income tied to the work performed in that state. The Tax Rules Are Complex
Stock options certainly offer the possibility of great returns and can incentivize an employee. When stock options are granted to foreign nationals who work in the U.S., they present unique tax challenges.
The U.S. retains taxing rights over income derived from U.S. employment, even after a person leaves America and becomes an NRA. Simply leaving the U.S. does not make the tax issues disappear. In order to minimize tax, the taxpayer must understand how the U.S. sources stock option income, the potential double taxation risks, and whether any tax treaty provisions can apply.
Proper planning such as use of foreign tax credit strategies and treaty benefits, can help reduce the tax burdens and avoid compliance problems. Given the complexity, an experienced U.S. tax professional should be consulted.
Stay on top of tax matters around the globe.
Reach me at vljeker@us-taxes.org
Visit my US tax blog www.us-tax.org It is an invaluable guide in all areas of U.S. international tax, keeping you ahead of US tax changes impacting your life, family or business, including tax developments on stock options.
NO ATTORNEY-CLIENT RELATIONSHIP OR LEGAL ADVICE
This communication is for general informational purposes only. It is not intended to constitute tax advice or a recommended course of action. Professional tax advice should be sought as the information here is not intended to be, and should not be, relied upon by the reader in making a decision.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

US Fed independence under threat, say economists, but no one expects a July rate cut- Reuters poll
US Fed independence under threat, say economists, but no one expects a July rate cut- Reuters poll

Yahoo

time28 minutes ago

  • Yahoo

US Fed independence under threat, say economists, but no one expects a July rate cut- Reuters poll

By Indradip Ghosh BENGALURU -The U.S. Federal Reserve's independence is under threat from mounting political interference, according to a clear majority of economists polled by Reuters, although no one expects a July interest rate cut despite a recent divergence in views among policymakers. President Donald Trump has made it almost a daily routine to personally attack Fed Chair Jerome Powell over the central bank's stance of holding rates due to tariff-related risks of higher inflation. A recent jump in inflation suggests businesses are now passing some of the tariffs onto consumers. Most Federal Market Open Committee members favor holding rates steady, but a few, including Governor Chris Waller and Trump appointee Fed Vice Chair for Supervision Michelle Bowman, have recently advocated a reduction as soon as July 30. Powell's term is set to expire in May 2026. Waller last week said he would accept the job as the bank's head if he was offered it by Trump. An over 70% majority of economists in the July 17-23 Reuters poll who answered an additional question, 36 of 50, said they were worried about the Fed's independence from political influence, including 10 who said they were very concerned. The remaining 14 said they were not. "I am more worried about the Fed's independence than I was a few months ago, and the main reason for that is the recent behaviour of Governors Bowman and Waller. It's very notable they are diverging from the consensus," said Philip Marey, senior U.S. strategist at Rabobank. "This year is still Powell's Fed. The current Fed is very cautious and wants to wait for the data and go only when they're sure ... It is kind of a policy paralysis at the moment and I don't think that will change as long as Powell has some grip on the FOMC," he added. All 105 economists said the Fed, which last cut its key interest rate to 4.25%-4.50% in December, will hold rates again at the conclusion of its July 29-30 meeting. Most respondents maintained their rate outlook or expected fewer reductions compared with a poll taken last month. A slight 53% majority of economists, 56 of 105, forecast a cut in September, in line with market pricing. But with less than half the year remaining, a clear consensus on where rates would be by end-2025 remains elusive. Economists are waiting for clarity on trade policies as a deadline for Trump's so-called "reciprocal" tariffs first announced in April approaches. That deadline of August 1 is itself an extension from a previous July 9 deadline. "Tariffs could affect things both in terms of higher inflation (and) it could slow the economy. The Fed doesn't know exactly what that mix is going to be and that's reason enough to wait," said Jonathan Millar, senior U.S. economist at Barclays. Just under two-thirds of forecasters expect one or two rate cuts this year, with nearly a fifth expecting no cuts at all. Interest rate futures are pricing in two reductions. The Fed will cut twice next year, poll medians showed. "We've had a very substantial easing of policy over the last few months just from the fact the dollar has weakened and improvements in equity markets. It's not as if things are really screaming out for a rate cut," Millar said. Inflation forecasts were broadly unchanged from last month, with economists forecasting it will average above the Fed's 2% target through at least 2027. The recent passage of Trump's signature spending bill, expected to add $3.4 trillion to an already enormous $36.2 trillion debt pile, poses a further risk of reigniting price pressures. The economy, which contracted 0.5% last quarter, is forecast to grow just 1.5% this year, a sharp slowdown from 2.8% in 2024. Next year, it was expected to expand 1.6%, a view that has remained steady since May. (Other stories from the Reuters global economic poll) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Amprion Announces Strategic Growth Initiatives, Expanding Access to Breakthrough SAAmplify Test
Amprion Announces Strategic Growth Initiatives, Expanding Access to Breakthrough SAAmplify Test

Yahoo

time28 minutes ago

  • Yahoo

Amprion Announces Strategic Growth Initiatives, Expanding Access to Breakthrough SAAmplify Test

Company Launches New Website, Scales Test Access Alongside Mayo Clinic, & Looks to Expand International Presence SAN DIEGO, July 23, 2025--(BUSINESS WIRE)--Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, has announced several strategic growth initiatives to broaden access to its SAAmplify-ɑSYN test. These initiatives include a comprehensive website refresh, expanded test availability via Mayo Clinic's network of hospitals and clinical sites, and ongoing preparations for international expansion. As part of its continuing growth and commitment to advancing early and accurate diagnosis, Amprion will showcase its latest developments and momentum at the Alzheimer's Association International Conference (AAIC), July 27-31, 2025, in Toronto, Canada. Attendees can connect with the Amprion team at booth #616. Following its recent collaboration with Mayo Clinic Laboratories, Amprion launched a newly redesigned website to meet the growing demand for its SAAmplify-ɑSYN test, which aids in the diagnosis of synucleinopathies. The breakthrough test can detect the presence of aggregates of alpha-synuclein protein, the underlying pathology of Parkinson's disease (PD), Lewy body dementia (LBD), multiple system atrophy (MSA), and Alzheimer's disease with Lewy bodies (AD + DLB), in cerebrospinal fluid. Launched earlier this month, the updated website is designed to provide patients, clinicians, and industry leaders with streamlined access to Amprion's latest research, information, and more. "As awareness and demand for our SAAmplify-ɑSYN test grow, we're working to ensure clinicians, researchers, and patients have better access to the tools and information they need," said Dr. Russ Lebovitz, CEO and co-founder of Amprion. "Our refreshed website and expanding partnerships are steps toward that goal, and we look forward to connecting with the global neuroscience community at AAIC." Due to this surge in awareness, Amprion is actively exploring international expansion opportunities, with plans to bring its test to European and global markets. Initial announcements regarding country-specific launch strategies are expected in Q4 2025. For more information or to schedule a meeting with Amprion at AAIC 2025, please visit About SAAmplify-ɑSYN (formerly SYNTap®) Amprion's SAAmplify-ɑSYN test is a first-in-class-qualitative Laboratory Developed Test (LDT) and the only seed amplification assay available to aid the diagnosis of synucleinopathies such as Parkinson's disease (PD), Lewy body dementia (LBD/DLB), and Alzheimer's disease (AD) with Lewy body co-pathology. The U.S. Food and Drug Administration (FDA) granted Amprion a Breakthrough Device Designation in 2019 for use of the test as an aid in the diagnosis of PD. The test became commercially available in the US in 2021. About Amprion Amprion is the global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing. Amprion's intellectual property surrounding SAA methodology extends to research, drug development, and commercialization. SAAmplify-ɑSYN (formerly SYNTap®) is the only seed amplification assay available to aid the diagnosis of synucleinopathies such as Parkinson's disease, Lewy body dementia, and Alzheimer's disease with Lewy body co-pathology. Amprion is also accelerating precision medicine for neurodegenerative disorders by helping biopharma partners identify new drug candidates and underlying pathologies. Learn more at or find us on LinkedIn. View source version on Contacts Media Contacts Liz RobinsonCG Lifelrobinson@ Karen SharmaCG Lifeksharma@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Boston Scientific trumps top and bottom-line forecasts, issues upbeat 2025 guide
Boston Scientific trumps top and bottom-line forecasts, issues upbeat 2025 guide

Yahoo

time28 minutes ago

  • Yahoo

Boston Scientific trumps top and bottom-line forecasts, issues upbeat 2025 guide

-- Boston Scientific (NYSE:BSX) posted second-quarter results that topped expectations, driven by strong organic growth and solid performance across key regions. Adjusted EPS came in at $0.75, beating the $0.73 consensus. Revenue rose to $5.06 billion, up 22.8% year-over-year, exceeding the $4.89 billion forecast. On an organic basis, sales increased 17.4% year-over-year. "This was another excellent quarter — marked by exceptional top-line performance — that delivered margin expansion and prioritized investment for future growth," said Mike Mahoney, chairman and CEO of Boston Scientific. The company saw strong double-digit growth in the U.S. and Asia-Pacific of 30.7% and 18%, respectively, while EMEA and Latin America posted more modest gains. Emerging markets also contributed with healthy growth. For the third quarter, it guided to EPS of $0.70 to $0.72, compared to expectations of $0.70. Looking further ahead, Boston Scientific expects full-year 2025 EPS in the range of $2.95 to $2.99, above the $2.92 consensus. Related articles Boston Scientific trumps top and bottom-line forecasts, issues upbeat 2025 guide These Under-the-Radar Stocks Offer Better Risk-Reward Ratio Than Nvidia After soaring 149%, this stock is back in our AI's favor - & already +25% in July

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store